CytomX Therapeutics (CTMX) Return on Capital Employed (2016 - 2025)
Historic Return on Capital Employed for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to 0.19%.
- CytomX Therapeutics' Return on Capital Employed fell 400.0% to 0.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.19%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.33% for FY2024, which is 4200.0% up from last year.
- Per CytomX Therapeutics' latest filing, its Return on Capital Employed stood at 0.19% for Q3 2025, which was down 400.0% from 0.44% recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Return on Capital Employed registered a high of 0.61% during Q1 2025, and its lowest value of 1.11% during Q4 2022.
- In the last 5 years, CytomX Therapeutics' Return on Capital Employed had a median value of 0.28% in 2021 and averaged 0.21%.
- As far as peak fluctuations go, CytomX Therapeutics' Return on Capital Employed tumbled by -7300bps in 2022, and later soared by 10000bps in 2023.
- CytomX Therapeutics' Return on Capital Employed (Quarter) stood at 0.42% in 2021, then plummeted by -166bps to 1.11% in 2022, then skyrocketed by 90bps to 0.12% in 2023, then surged by 587bps to 0.57% in 2024, then plummeted by -67bps to 0.19% in 2025.
- Its Return on Capital Employed was 0.19% in Q3 2025, compared to 0.44% in Q2 2025 and 0.61% in Q1 2025.